Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020

AD Sherry, AW Hahn, ZR McCaw… - JAMA Network …, 2024 - jamanetwork.com
Importance Subgroup analyses are often performed in oncology to investigate differential
treatment effects and may even constitute the basis for regulatory approvals. Current …

Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials

AD Sherry, P Msaouel, TA Lin, J Abi Jaoude… - BMJ …, 2024 - bmjoncology.bmj.com
Objective Estimations of the treatment effect on overall survival (OS) may be influenced by
post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT …

Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma

SG Gray, T Meirson, L Mutti - Journal of Thoracic Oncology, 2024 - Elsevier
In recent years, the treatment paradigm for pleural mesothelioma (PM) has been expanded
after the development and rollout of immune checkpoint inhibitors (ICIs), 1 whereas the …